Turing’s Drug Price Gouging Gives Politicians A Gift And Biotech A Perhaps Enduring Headache

September 23, 2015

All day Monday, on TV and Twitter you could hear investors, Big Pharma, biotech executives and politicians all saying the same thing: “What’s next?”

Continue Reading

WBB Securities Sponsors BioCentury’s Annual NewsMakers Conference

September 1, 2015

WBB Securities is a sponsor of this year’s NewsMakers in the Biotech Industry conference.

Continue Reading

Greece Is On The Verge Of A Health Catastrophe

July 15, 2015

Over 2,500 years ago, Thucydides, known as the father of scientific history because he relied on facts and his observations rather than divine intervention to explain events, once described a plague that struck Athens. As disease spread unchecked and healthcare standards disappeared almost 1/3 of the city’s population perished.

Continue Reading

Did Celgene’s Billion Dollar Deal With Juno Just Save The Biotech Bull Market?

June 30, 2015

Just when you think a biotech bear market is about to descend, the bulls come rushing in.

Continue Reading

An Immunotherapy To Treat Brain Cancer Rises In The Wake Of A Public Loss

June 2, 2015

Word of Beau Biden, Jr.’s death stunned the nation. It was a sudden loss, unexpected news that chimed and buzzed over smartphones everywhere and then flashed over television screens across the country.

Continue Reading

Analyst Interview: As Cancer Immunotherapy Turns 125, WBB Securities’ Steve Brozak Ponders What Investors Can Expect from Biotech Next

May 27, 2015

Steve Brozak sees a bubble getting larger, and he is anticipating the time when biotech stocks pull back to take a breather, like all high-flying markets ultimately do.

Continue Reading

WBB Securities Acts as Financial Advisor on $60 Million Loan for Navidea Biopharmaceuticals

May 11, 2015

WBB Securities acted as financial advisor to Navidea Biopharmaceuticals regarding a term loan with CRG (formerly Capital Royalty LP). Under the terms of the agreement, CRG will provide Navidea with initial funding of $50 million.

Continue Reading

WBB Securities Acts as Placement Agent for up to $25 Million in Equity Financing for Cytori Therapeutics

May 8, 2015

WBB Securities acted as placement agent to a transaction for Cytori Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing autologous cell therapies from adipose tissue to treat a variety of medical conditions.

Continue Reading

WBB Securities Co-Manages $25 Million Public Offering for TetraLogic

May 1, 2015

WBB Securities is acting as co-manager to a transaction for TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology.

Continue Reading

M&A Mania Infects Generic Drug Companies

April 22, 2015

There are very few assurances in life, but in the field of generic pharmaceuticals, there are three certainties we are about to witness

Continue Reading